TCR2 Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer
CAMBRIDGE, Massachusetts, June 27, 2022 – RCS2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T-cell therapies for patients with solid tumors, today announced the appointment of Eric Sullivan as Chief Financial Officer, where he will be responsible for directing all aspects of financial management and capital market strategy as well as overseeing investor relations and certain business operations.
“We are delighted to announce that Eric Sullivan is joining the TCR2 team as CFO,” said Garry Menzel, Ph.D., President and CEO of TCR2 Therapeutic. “Eric brings a wealth of finance, strategy, operations and leadership experience to the company, having held several positions in high-growth companies during his tenure in the biotech industry. As we we are preparing for several key inflection points in our two clinical programs, gavo-cel and TC-510, his appointment will further strengthen our team to meet the challenges ahead and maximize value for all of our constituents during this next phase of transformational growth.”
Mr. Sullivan brings to TCR2 nearly 20 years of finance and operations experience in the biotechnology industry, working on financial management, strategic planning, fundraising and capital markets transactions in both public and private markets. Prior to joining the company, he was President, CFO and COO of Triplet Therapeutics, where he led corporate finance, business development and operations. Prior to that, Sullivan led finance as senior vice president at Gemini Therapeutics and Oncorus. Earlier in his career, he held senior financial positions at bluebird bio and Merrimack Pharmaceuticals. Mr. Sullivan holds a BS in Accounting from Bentley University and is a Certified Public Accountant (CPA).
“With an extraordinary management team and an ambitious vision to change the paradigm of treatment for solid tumors, TCR2 represents a leading cell therapy company in a unique position, especially for the many cancer patients who have limited or no treatment options,” said Sullivan. “Joining at this inflection point is an incredible opportunity to add real value to the company on its growth trajectory with two key programs in the clinic and several more in the pipeline.”
About TCR2 Therapeutic
TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T-cell therapies for patients with solid tumors. The Company is focused on the discovery and development of product candidates against novel and complex targets using its proprietary Fusion Construct T cells (TRuC) T-cell receptor (TCR)®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from across the TCR, independent of human leukocyte antigens (HLA). For more information on the TCR2please visit www.tcr2.com.
This press release contains forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may”, “will”, “could”, “should”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimates”, “predicts”, “plans”, “research”, “effort”, “potential”, “continue” or the negative form of these words or other similar expressions may be used to identify forward-looking statements. These forward-looking statements include, but are not limited to, express or implied statements regarding the therapeutic potential of gavo-cel,TC-510 and TCR2other product candidates, expectations regarding future growth and prospects, future clinical development, partnership and commercialization plans, development of the Company’s TRuC-T cells, their potential characteristics, applications and clinical utility , and the potential therapeutic applications of the Company’s TRuC-T T Cell Platform.
The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: the uncertainties inherent in clinical studies and the availability and timing of data from ongoing clinical studies. studies; whether the intermediate results of a clinical trial will be predictive of the final results of the trial; whether the results of preclinical studies or previous clinical studies will be predictive of the results of future trials; the expected timing of submissions for regulatory approval or review by governmental authorities, including consideration under expedited approval processes; eligibility for orphan drug designation; regulatory approvals to conduct trials or market products; TCR2the ability to maintain sufficient manufacturing capabilities to support its research, development and commercialization efforts, including TCR2the ability to obtain additional manufacturing facilities; if TCR2cash will be sufficient to fund TCR2predictable and unpredictable operating expenses and capital expenditure needs, the impact of the COVID-19 pandemic on the TCR2ongoing operations; and other risks set out under “Risk Factors” in the TCR2most recent annual report on Form 10-K, most recent quarterly report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely on forward-looking statements as predictions of future events. Although TCR2 believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the results, levels of activity, performance or future events and circumstances reflected in the forward-looking statements will be achieved or occur.
Further, except as required by law, neither TCR2 nor does any other person assume responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Investor and media contact:
Senior Director, Investor and Corporate Relations
Communications (617) 949-5667